INTRODUCTION
Cytoplasmic mRNA in Eukaryotes is modified at the 5' end by a protective cap structure (1,2). The cap prevents premature degradation by 5'-exonucleases and recruits proteins required for pre-mRNA splicing, mRNA transport, and initiation of protein biosynthesis. The key invariable structural feature of 5' cap is the 7-methylguanosine moiety linked by a 5',5'-triphosphate chain to the first transcribed nucleotide. This m A vary between studied cell lines, but usually is more than 50% (4-7). Numerous studies revealed that the 5' cap composition is dependent on the organism, tissue or cell type (5, 8, 9 ).
The 5' cap structures and cap proximal RNA sequences have been initially investigated by radioactivity-based chemo-enzymatic methods (1,2,4,9), but more recently, transcriptome-wide MSbased techniques enabled more robust and quantitative analyses leading to interesting discoveries (12). Much less is known about the role of cap 2 or N6 methylation of adenine. Initially, the presence of m 6 A m at transcription start site (TSS) was linked to increased translation efficiency and transcripts stabilization (13, 14) . However, recently these findings were re-examined to reveal that the effects of adenine N6 methylation on mRNA stability and translation are rather sequence-dependent, and not due to the presence of m 6 A m itself (15). 5'-Terminal mRNA sequence diversity appears to be speciesdependent as well. For instance, in budding yeast a strong preference to start transcription of proteincoding genes with purines (A and G) was observed (16, 17) , whereas in human cells m 7 G-capped mRNAs frequently start with A,G, C, and m 6 A, but not U, which is used more than 100-times less frequently (18) (19) (20) . Interestingly, transcription of particular genes can be initiated at multiple sites, which leads to production of mRNAs with different 5'UTRs (untranslated regions) (17, 21) . Although the physiological significance and functional consequences of TSS and cap-proximal sequence diversity is poorly understood, it has been suggested that it is linked to translation regulation (20, 21) .
Deciphering the exact biological role of nucleotides at TSS in mRNA is valuable not only for understanding the regulation of gene expression, but is also of therapeutic relevance. For clinical gene therapy applications it is beneficial to apply mRNAs with superior translational properties and improved stability (22).
The biological significance of 5' cap variations in different organisms could be systematically investigated using in vitro transcribed (IVT) mRNAs as molecular tools. Unfortunately, the currently available capping methods do not offer an easy access to differently capped mRNAs. The state of the art in preparation of in vitro transcribed mRNA is co-transcriptional capping with m 7 GpppN-derived dinucleotide (23). The transcription reaction is typically carried out by bacteriophage RNA polymerase (T7, T3, SP6) in the presence of a single (ss) or double stranded (ds) DNA template containing an appropriate promoter sequence and the mix of four NTPs. The polymerase initiates the transcription activity relationship for these variously capped RNAs. We assess how the cap structure variations influence quality of IVT transcribed mRNAs, overall protein expression of exogenously delivered mRNA in different mammalian cell lines, affinity for translation initiation machinery, susceptibility to decapping, and cytokine response in the absence or the presence of RNA impurities. We find that the effect of the first transcribed nucleotide identity and its methylation status is highly dependent on the cell line, with JAWS II dendritic cells being most sensitive to structural changes within mRNA 5' end.
We also find that mRNA purity is the most important factor influencing mRNA expression in all investigated cells via nucleic acid recognition pathways activation. The means to control adjuvanticity of therapeutic mRNA are desired, since mild immuno-stimulation is required for some applications, e.g. anticancer vaccines, but too strong immune response can lead to shutdown of global translation or induction of apoptosis (29). 
MATERIAL AND METHODS

Synthesis of trinucleotide cap analogs
General information
Solvents, chemical reagents, and starting materials, including phosphoramidites were purchased from commercial sources. P-imidazolides of N 7 -methylguanosine 5'-diphosphate (m GDP-Im), trielthyammonium salt of adenosine 5′-monophosphate, and 6-chloropurionoriboside 5′-monophosphate were synthesized according to the previously described protocols (24, 30, 31) .
Dinucleotides pNpG and trinucleotide cap analogs were isolated from the reaction mixtures by ion-exchange chromatography on a DEAE Sephadex A-25 (HCO 3 -form) column. For this, the column was loaded with the reaction mixture and washed thoroughly with water until the eluate did not form a precipitate with AgNO 3 solution. Nucleotides were then eluted using a linear gradient of triethylammonium bicarbonate (TEAB) in deionized water and the collected fractions were analyzed spectrophotometrically at 260 nm. The yields were calculated on the basis of optical density (mOD = absorbance of the solution × volume in mL) of combined fractions measured in 0.1 M phosphate buffer pH 7.0 at 260 nm. After evaporation under reduced pressure with repeated additions of 96% ethanol and then acetonitrile, nucleotides were isolated as triethylammonium salts. The final compounds were additionally purified using semi-preparative RP-HPLC using a Vydac Denali (HiChrom) C18 RP HPLC column (150 × 10 mm, 5 μ m, 120Å, flow rate 5.0 mL/min) with UV detection at 254 nm and isolated from the eluate by repeated freeze-drying.
The structure and homogeneity of each compound was confirmed by re-chromatography by RP-HPLC, high-resolution mass spectrometry using negative electrospray ionization (HRMS-ESI) and in case of N 6 -methylated phosphoramidites, methylated adenosine 5′-monophosphates and p m6 A m pG by 1 H, COSY and 31 P NMR. Analytical HPLC was performed using a Supelcosil LC-18-T HPLC column (4.6 × 250 mm, flow rate 1.3 mL/min) with a linear gradient of 0-50% of methanol in 0.05 M ammonium acetate buffer (pH 5.9) over 15 min and UV detection at 254 nm. Mass spectra were recorded with LTQ Orbitrap Velos (Thermo Scientific, high resolution). NMR spectra were recorded at 25 °C with a Bruker Avance III 500 MHz spectrometer equipped with a high stability temperature unit using 5 mm PABBO BB/19F-1H/D Z-GRD probe at 202.50 MHz ( 31 P NMR). were dissolved in CH 2 Cl 2 (10.9 mL) and mixed with aqueous solution (10.9 mL) of tetrabutylammonium bromide (351 mg, 1.09 mmol) and NaOH (451 mg, 10.9 mmol). The mixture was stirred vigorously for 30 min and then diluted with water (100 mL) and diethyl ether (100 mL). The layers were separated and the aqueous phase was extracted twice with diethyl ether (50 mL).
Organic layers were combined, dried over Na 2 SO 4 and evaporated. The residue was dissolved in CH 2 Cl 2 with 0.5%v/v triethylamine and evaporated with silica-gel. The product was isolated by flash chromatography on 40 g silica-gel column using gradient elution (0→100% ethyl acetate in n-hexane) were treated with 20% (v/v) diethylamine in acetonitrile to remove 2-cyanoethyl protecting groups.
Finally, the solid support was washed with acetonitrile and dried with argon.
The product was cleaved from the solid support and deprotected with AMA (methylamine/ammonium hydroxide 1:1 v/v ; 55 °C, 1 h), evaporated to dryness and redissolved in DMSO (200 μ L). The TBDMS groups were removed using triethylammonium trihydrofluoride (TEA·3HF; 250 μ L, 65 °C, 3 h), and then the mixture was cooled down and diluted with 0.25 M NaHCO 3(aq) (20 mL). The product was isolated by ion-exchange chromatography on DEAE Sephadex (gradient elution 0-0.9 M TEAB) to afford after evaporation triethylammonium salt of pNpG dinucleotide. The scales, yields, and HRMS data for particular dinucleotides are summarized in Table 1 . 
Trinucleotide cap analogs -general procedure
Triethylammonium salt of pNpG was dissolved in DMSO (to 0.05 M) followed by addition of m 7 GDPIm (2-5 eqv) and anhydrous ZnCl 2 (20-40 eqv). The mixture was stirred for 24-48 h and then the reaction was quenched by addition of 10 volumes of aqueous solution of EDTA (20 mg/mL) and NaHCO 3 (10 mg/mL). The product was isolated by ion-exchange chromatography on DEAE Sephadex (gradient elution 0-1.2 M TEAB) and purified by semi-preparative RP HPLC (gradient elution 0-15% acetonitrile in 0.05 M ammonium acetate buffer pH 5.9) to afford -after evaporation and repeated freeze-drying from water -ammonium salt of trinucleotide cap m 7
GpppNpG. The structure of the compounds was confirmed by high resolution mass spectrometry (HRMS). The reagent amounts, yields, and HRMS data for particular cap analogs are summarized in Table 2 . Quality of transcripts was checked on 15% acrylamide/7 M urea gels, whereas concentration was determined spectrophotometrically. To remove in vitro transcription by-products of unintended size RNA samples were gel-purified using PAA elution buffer (0.3 M sodium acetate, 1 mM EDTA, 0.05% Triton X-100), precipitated with isopropanol and dissolved in water. In order to obtain capped fraction of in vitro transcribed short RNAs, transcripts were treated with 5'-polyphosphatase (Epicentre) and Xrn1 (New England Biolabs) as described previously (33). Finally, to generate homogenous 3'-ends in those short RNAs, the transcripts (1 µM) were incubated with 1 µM DNAzyme 10-23 (TGATCGGCTAGGCTAGCTACAACGAGGCTGGCCGC) in 50 mM MgCl 2 and 50 mM Tris-HCl pH 8.0 for 1 h at 37 °C (32), which allowed to produce 3'-homogenous 25-nt RNAs. The transcripts were precipitated with ethanol and treated with DNase I before analysis.
mRNA mRNAs encoding Gaussia luciferase were generated on template of pJET_T7_Gluc_128A plasmid digested with restriction enzyme AarI (ThermoFisher Scientifics). The plasmid was obtained by cloning the T7 promoter sequence and coding sequence of Gaussia luciferase into pJET_luc_128A
(34). Typical in vitro transcription reaction (20 µl) was incubated at 37 °C for 2 h and contained: RNA Pol buffer (40 mM Tris-HCl pH 7.9, 10 mM MgCl 2 , 1 mM DTT, 2 mM spermidine), 10 U/µl T7 RNA polymerase, 1 U/µl RiboLock RNase Inhibitor, 2 mM ATP/CTP/UTP, 0.5 mM GTP, 3 mM cap analog of interest and 50 ng/µl digested plasmid as a template. Following 2 h incubation, 1 U/µl DNase I was added and incubation was continued for 30 min at 37 °C. The crude mRNAs were purified with NucleoSpin RNA Clean-up XS (Macherey-Nagel). Quality of transcripts was checked on native 1.2% 1xTBE agarose gel, whereas concentration was determined spectrophotometrically. To remove uncapped RNA, transcripts were treated with 5'-polyphosphatase (Epicentre) and Xrn1 (New England Biolabs) as previously described (33). Finally, to deplete dsRNA by-products of in vitro transcription, mRNAs were purified on Agilent Technologies Series 1200 HPLC using RNASep™ Prep -RNA Purification Column (ADS Biotec) at 55 °C as described in (35). For mRNA purification a linear gradient of buffer B (0.1 M triethylammonium acetate pH 7.0 and 25% acetonitrile) from 35% to 50% in buffer A (0.1 M triethylammonium acetate pH 7.0) over 18 min at 0.9 ml/min was applied. mRNAs was recovered from collected fractions by precipitation with isopropanol. Quality of transcripts was checked on native 1.2% 1xTBE agarose gel, whereas concentration was determined spectrophotometrically. Gaussia luciferase, 50 µl of 10 ng/ml h-coelenterazine (NanoLight) in PBS was added to 10 µl of cell cultured medium and the luminescence was measured on Synergy H1 (BioTek) microplate reader.
Dot blot analysis
Fluorescence Quenching Titration (FQT) binding assay for eIF4E
Murine eukaryotic translation initiation factor 4E (eIF4E, residues 28-217) was expressed and purified as described previously (36). Titration experiments were performed at 20 °C in 50 mM Hepes/KOH buffer pH 7.20 containing 100 mM KCl, 0.5 mM EDTA, and 1 mM DTT. Aliquots ( intensities were corrected for sample dilution and inner filter effect (37). Equilibrium association constants (K AS ) were determined by fitting the theoretical dependence of fluorescence intensity on the total concentration of the cap analogue to the experimental data points, according to the equation described previously (37). Each experiment was repeated three times and the association constants K AS were calculated as weighted averages, with the weights taken from reciprocal standard deviations squared. The dissociation constants K D reported in Table 2 were calculated as K AS -1 .
Chemical shift perturbation experiments with eIF4E
Protein expression and purification. 15 N labelled murine eukaryotic translation initiation factor 4E (eIF4E, residues 28-217) was expressed in M9 media (pH = 7.4) containing: Na 2 HPO 4 (6 g/L), 
RNA decapping assay
Human Dcp2 was expressed in E. coli and purified as described previously (39). Capped RNA (30 ng)
were subjected to digestion with 10 nM hDcp2 in decapping buffer (50 mM Tris-HCl pH 8.0, 50 mM NH 4 Cl, 0.01% NP-40, 1 mM DTT, 5 mM MgCl 2 and 2 mM MnCl 2 ). Reactions were performed at 37 °C for the indicated times and terminated by adding equal volume of loading dye (5 M urea, 44%
formamide, 20 mM EDTA, 0.03% bromophenol blue, 0.03% xylene cyanol). RNAs after hDcp2 treatment were resolved electrophoretically on denaturing 15% acrylamide / 7 M urea 1xTBE gel stained with SYBR Gold (Invitrogen) and visualized using a Typhoon FLA 9500 (GE Healthcare).
Cytokine and nucleic acid recognition pathway elements determination by RT-qPCR 10 4 HeLa or 3T3 cells, or 2.5·10 4 JAWS II cells were seeded in 96-well plates as described above.
Cells in each well were transfected for 5 h using a mixture of 0.3 µl Lipofectamine MessengerMAX
Transfection Reagent and 25 ng mRNA encoding Gaussia luciferase in 10 µl of Opti-MEM. RNA extraction and subsequential RT-qPCR analysis of chosen gene expression level was performed according to manufactures' instruction (Ambion Power SYBR Green Cells-to-CT Kit (ThermoFisher Scientifics)). The GAPDH gene was used for normalization of relative expression values. All reactions were run in three independent biological replicates. Sequence of all used primers is shown in Table   S1 .
Cytokine production assay -flow cytometry JAWS II cells were grown as mentioned above. 10 4 cells were seeded at the day of experiment in 100 µl medium without antibiotics per well of 96-well plate. Cells in each well were transfected for 24 h using 0.3 µl Lipofectamine MessengerMAX Transfection Reagent, 25 ng mRNA and 10 µl Opti-MEM.
After transfection cell supernatants were collected and subjected to cytokine production analysis using LEGENDplex™ Mouse Anti-Virus Response Panel (13-plex) (BioLegend) on BD FACS Canto II flow cytometer using BD FACSDiva 8.0 software for acquisition and BioLegend's LEGENDplex™ Data Analysis Software for data analysis.
RESULTS
Trinucleotide cap analogues are suitable for the preparation of IVT RNA
The trinucleotides were synthesized by a combination of solid-phase and solution chemistry (Scheme 1) followed by two-step purification procedure. The key starting materials, dinucleotide 5'-phosphates (pNpG) were first synthesized using phosphoramidite approach on a highly-loaded solid support. The product was cleaved and deprotected using amonium The nearly quantitative conversion of pNpG into trinucleotide cap was usually achieved within 24 h.
The product was isolated from the reaction mixture by ion-exchange chromatography and additionally purified by RP HPLC to give ammonium salt suitable for biological experiments.
Scheme 1. General approach to the synthesis of trinucleotide cap analogues.
We next tested how efficiently are the trinucleotide cap analogs incorporated into RNA during in vitro transcription (IVT) and how the 5' end homogeneities of resulting RNAs compare to the typically 5'-capped RNAs. The IVT reactions were then performed from a DNA template containing the Φ 6.5 promoter followed by a sequence of 35 nt using a standard protocol for T7 RNA polymerase (Pol T7). To ensure high capping efficiency, a 6-fold higher trinucleotide concentration was used over GTP. The resulting transcripts were gel purified, trimmed at the 3' end by DNAzyme 10-23 to reduce 3'-end heterogeneity and facilitate 5'-end analysis (32), followed by a purification and separation of the products in high-resolution polyacrylamide gel ( Figure 2A) . Importantly, all the tested trinucleotides were fairly efficiently incorporated into RNA under these conditions, as indicated by the presence of bands migrating slower compared to uncapped RNA (RNA 25 ). For some cap analogs only a single major capped product was observed, whereas for others additional longer products were also visible, indicating for an addition of untemplated nucleotide(s) at the 5'-end, which is a known feature for transcripts produced by Pol T7 from certain promoters (41). Notably, the highest 5' end heterogeneity was observed for RNA obtained using dinucleotide cap analogs (m The capping efficiencies for the obtained RNAs ranged from 54 to 90% ( Figure 2A and Table   3 ). The highest capping efficiency was observed for trinucleotides featuring a purine nucleotides at the position of the first transcribed nucleotide ('purine trinucleotides'): m Table 3 ; (B) The proposed major transcription initiation events explaining the differences in capping efficiencies and lengths between RNAs obtained in the presence of different cap analogs. A typical initiation event involves annealing of guanosine from the cap analog with +1 cytosine in the antisense strand of the template. Exceptions are A-trinucleotides, which can anneal with both -1 and +1 sites forming A-T and G-C pairs thereby providing more efficient capping, and G-trinucleotides, which can anneal with +1 and +2 sites forming two G-C pairs thereby providing more efficient capping and 1 nt shorter transcription product.
This assumption is further supported by the fact that the transcripts obtained with G-trinucleotides are one nucleotide shorter than those obtained with other trinucleotides, which can also be explained by a preference for double pairing with the template during transcription initiation ( Figure 2B ). To additionally confirm this observation we subjected the transcripts to sequential treatment RNA with polyphosphatase and Xrn1 (to remove uncapped RNAs), followed by exhaustive decapping of the remaining transcripts by Dcp2 ( Figure S1 ). The migration of the resulting decapped RNAs confirmed that transcripts obtained in the presence of G-trinucleotides were shorter than other transcripts. This experiment also indirectly confirmed that the trinucleotides are incorporated into RNA in the correct orientation. Normalized overall protein expression
[c] Susceptibility to hDcp2
GpppApG 89 ± 1 1.00 ± 0.12 (1.00 ± 0.05
[f] )
1.00 ± 0.14 1.00 ± 0.23 (1.00 ± 0.06 n.d. 0.18 ± 0.02 [f] 80.0 ± 1.9 [g] n.d.
GpppGpG 80 ± 1 0.33 ± 0.17 (0.37 ± 0.02) [f] 0.34 ± 0.08 0.05 ± 0.01 (0.08 ± 0.01) [f] 22.7 ± 0.9 0.10 ± 0.02
GpppGmpG 86 ± 3 0.24 ± 0.17 (0.40 ± 0.01) [f] 0.41 ± 0.22 0.12 ± 0.01 (0.32 ± 0.01) [f] 22.8 ± 0.6 0.08 ± 0.03 Figure S7 ). The cell medium was exchanged after each measurement so that only the activity of newly produced protein is quantified at each time point. Data points present mean values ± SD (n = 6 for 3T3 and JAWS II; n = 9 for HeLa; obtained with mRNAs generated in two independent IVT reactions). Turkey's multiple comparisons test.
The affinity for translation initiation factor 4E is similar for cap 0 and cap 1 trinucleotides
To assess how the identity and methylation status of the cap influences the affinity to translational machinery, we determined binding affinities for selected trinucleotide cap analogues to canonical translation initiation factor, eIF4E. The measurements were performed using time-synchronized fluorescence quenching titration (tsFQT), which delivers highly precise data on equilibrium binding constants (42). To this end, eIF4E protein was titrated with increasing concentrations of cap 0 and cap 1 variants of A-, G-, or C-trinucleotides and fluorescence intensity changes at 337 nm (upon 280 nm excitation) were monitored ( Figure 4A ). The determined dissociation constant values (K D ; Table 3 , Figure 4B ), indicated that among the different nucleobases G conferred the highest affinity for eIF4E, albeit the differences were generally modest. The presence of methyl group at 2'-O position of ribose did not stabilize cap-eIF4E interaction. In most cases, the addition of 2'-O-methyl group did not influence the binding affinity significantly, and in the case of m GpppG (PDB id: 1L8B); grey colour indicates residues that belong to the C-terminal loop but
were not assigned in HSQC spectra (E and incubated with recombinant hDcp2 for 60 min, followed by the high resolution polyacrylamide gel analysis of products taken at different time-points ( Figure 5A , Figure S8 ). To compare the decapping susceptibilities of RNAs bearing different caps, the fraction of capped RNA remaining in each sample was plotted as a function of time ( Figure 5B-F) . We found that neither the 2'-O-methylation of the ribose nor N6-methylation of adenosine influenced in vitro susceptibility of RNA to hDcp2 ( Figure   5A ,B, Figure S8 ). Similarly, other transcripts carrying caps 0 had decapping susceptibilities indistinguishable from cap 1 counterparts ( Figure 5B-E) . However, there were some differences in susceptibility to hDcp2 among different first transcribed nucleotides, namely RNAs with guanine were the most stable (decapping susceptibility for RNAs with G and G m at time point 15 min was 0.1 and 0.08, respectively), while transcripts with adenine were the most prone to decapping (decapping susceptibility for RNAs with A and A m as first transcribed nucleotide was 0.48 and 0.45, respectively) ( Figure 5F , Table 3 ). 1 Table 3 .
Although it has been previously reported that m 6 A modulates mRNA stability through decreasing susceptibility to decapping (13, 14) , the most recent findings are in agreement with our in vitro studies and indicate that the observations initially attributed to m 6 A function are actually RNA sequencedependent (15).
IVT mRNA purity is the most important determinant of protein expression in cells
To our knowledge, the finding that the effect of the identity and methylation status of the first transcribed nucleotide is strongly dependent on the type of cultured cells was unprecedented in the literature and thus somehow unexpected. Nonetheless, it has been suggested that the presence of In the first variant mRNAs were purified by the multistep procedure described above, which included treatment with 5'-polyphosphatase, which converts RNA triphosphates to RNA monophosphates, followed by treatment with Xrn1, which degrades only 5'-phosphorylated ssRNA (but not dsRNA),
followed by purification with a commercially available kit, and RP-HPLC as the final step (as above;
referred to as an HPLC-purified mRNA). In the second variant the same enzymatic processing steps were followed by purification using commercial kit only (without HPLC; referred to as a crude mRNA).
We first compared how these processing steps influence the levels of dsRNA impurities in capped and uncapped mRNA samples by using a dot blot assay with dsRNA-specific antibodies (Figure 6 insert). As expected, we found that HPLC purification is a necessary step to diminish dsRNA content below the antibody detection levels. Surprisingly, the anti-cap antibody used as a reference detected the cap only in crude mRNA, which suggests that the majority of dsRNA in these preparations is also m 7 G-capped, and after its removal cap levels fall below the detection limit. Next, the protein expression in JAWS II and 3T3-L1 cells was determined in the same way as above ( Figure 6A ,B). We observed that regardless the cell type and the cap structure carried by mRNA, the presence of capped dsRNAs strongly hampered protein yield ( Figure 6B ). Transfection of crude IVT mRNA capped with cap 0 or cap 1 into 3T3-L1 cells resulted in 21-and 9-fold reduction in expression levels, respectively, compared to the expression levels from the same amount of corresponding HPLCpurified mRNA. This effect was even more pronounced for JAWS II cells, in which crude transcripts bearing cap 0 and cap 1 were almost 300-and over 400-fold, respectively, less efficiently expressed than HPLC-purified counterparts. Moreover, in the case of crude mRNA we noticed a differentiation between mRNAs carrying cap 0 and cap 1 structures in 3T3-L1 cells that was not observed for HPLCpurified transcripts. Namely, mRNA capped with m 7
GpppApG was translated about 2-fold lower than mRNA capped with m 7
GpppA m pG ( Figure 6B ). Cells were transfected with 25 ng of HPLC-purified mRNA (A-C) or crude mRNA (D-E) for 5 h. mRNA expression analysis pre-and post-transcfection for the indicated genes was carried out using RTqPCR. Bars represent mean value of mRNA level change (fold change) ± SEM (n = 3). The data was obtained with mRNAs generated in two independent in vitro transcription reactions. Only statistically significant differences were marked on the graph (one-way ANOVA with Turkey's multiple comparisons test). Before averaging the results, the data sets in each independent replicate were normalized to unpurified 5'-triphosphorylated RNA (pppG-RNA); then, the average values were normalized to mock samples to give the final normalized fold change values.
We found a significant induction of all investigated genes upon transfection of crude 5'-triphosphorylated IVT mRNA into HeLa and 3T3-L1 ( Figure 7A,B) . In contrast, the transfection with HPLC-purified IVT mRNA did not trigger measurable immune response at the mRNA expression level regardless of the presence and identity of the 5' cap ( Figure 7A ,B). The same method was employed to assess changes in gene expression in mouse immature DCs (JAWS II) ( Figure 7C ). However, quite surprisingly, in this case the RT-qPCR analysis did not reveal any changes in gene expression, even upon transfection with unpurified pppG-mRNA.
Next, we asked whether these observations will be altered in the presence of dsRNAs impurities. Thus, we performed analogous experiments using either unpurified and enzymatically unprocessed ppp-mRNA or crude capped IVT mRNAs that were not subjected to HPLC purification, but were treated with 5'-polyphosphatase and Xrn1 in order to eliminate all 5'-triphosphorylated (uncapped) ssRNAs that could interfere with the measurement of cap-dependent responses. We confirmed that dsRNA species are still abundantly present in IVT mRNA after such enzymatic processing using dot blot analysis ( Figure S4 ). We anticipate that this procedure converts also 5'-triphosphate dsRNA into corresponding 5'-monophosphate, which is less immunogenic, although we did not verify this experimentally. These transcripts capped either with m 7
GpppApG, m 7
GpppA m pG-RNA or uncapped were then transfected into 3T3-L1 and HeLa cells to investigate expression of selected cytokines and nucleic acid recognition pathways elements by RT-qPCR (JAWS II cells were not included in this experiment since in the first experiment we did not see any changes in expression levels even for crude triphosphate mRNA, Figure 7C ). As expected, we found that the presence of dsRNA impurities in IVT mRNA leads to upregulation of gene expression in HeLa and 3T3-L1 cell lines ( Figure 7D,E) . Interestingly, the extent of this up-regulation was highly dependent on the type of the cap structure used in IVT. Crude mRNAs obtained with m 7 GpppApG increased the expression level of almost all investigated genes, however the effect was usually weaker than for uncapped mRNAs. In contrast, mRNAs carrying cap 1 usually did not alter gene expression in a statistically significant manner (compared to mock), and in few instances they did, the effect was notably weaker than for cap 0 mRNAs ( Figure 7D ,E). It should be emphasized here that the observed differences in immune response activation most likely do not arise exclusively from the chemical nature of the studied mRNAs, but rather from the overall properties of all RNA species present in the transcription batch. In particular, the chemical nature of dsRNA impurities may contribute to the observed differences for uncapped, cap 0-and cap 1-capped mRNAs (further elaborated in discussion).
Dendritic cells respond to crude mRNAs by cytokine production
Since we did not observe any differences in gene expression levels for RNA sensors and ISGs upon transfection of DCs with IVT mRNA, we took another approach widely used to study DCs response to IVT mRNA. Namely, the levels of various cytokines secreted to the cell culture medium were Figure S9 .
DISCUSSION
In vitro transcribed mRNAs have been widely used as research tools in biochemistry, biotechnology and cell biology and, recently, have also emerged as promising candidates for the next generation gene therapeutics. As such, efforts have been made to optimize mRNA structure and manufacturing procedures in order to benefit both the research and therapeutic applications, which include sequence optimization (UTRs -untranslated regions and codon optimization), chemical engineering (use of pseudouridine, 5-methylcytosine or chemically modified 5' caps), and optimization of in vitro transcription and mRNA purification protocols, altogether providing methods for improving cellular stability and translational potential of mRNA (55-58). Our work aimed to contribute to this field by looking for optimal structural variants of the natural 5' cap that ensure high expression of exogenously delivered IVT mRNA.
To address this issue we synthesized a set of trinucleotide cap analogs as reagents for cotranscriptional RNA capping, which enabled generation of RNAs with a specified identity and methylation status of the first transcribed nucleotide. We demonstrated that these compounds, when used in IVT reaction with T7 polymerase and standard promoter sequence (Φ6.5), produce RNAs of superior quality compared to state-of-the-art dinucleotide caps. Using these molecular tools we produced a set of reporter mRNAs to study expression in cultured cells. It has been previously reported that IVT transcribed mRNAs obtained with polymerase T7 contain different immunogenic impurities, dsRNA in particular. Additionally, even highly optimized protocols for co-transcriptional capping provide maximum capping efficiencies of 90%, meaning that at least 10% of the batch remains uncapped. Trying to minimize interferences from these impurities in our experiments, we subjected IVT mRNAs to multistep purification, which resulted in enzymatic removal of uncapped ssRNAs and depletion of double stranded impurities using HPLC. These HPLC-purified differently Such optimization should be straightforward with the use of trinucleotide cap analogs developed here.
Whether our findings for exogenously delivered mRNAs are linked to any endogenous mRNA regulatory mechanism remains to be elucidated. 
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